Ironwood Pharma (IRWD) Tops Q3 EPS by 13c; offers guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.24, $0.13 better than the analyst estimate of $0.11. Revenue for the quarter came in at $122.06 million versus the consensus estimate of $72.9 million.

GUIDANCE:

Ironwood Pharma sees FY2025 revenue of $290-310 million, versus the consensus of $279.4 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Trump: Walmart will be lowering prices
• Sky Harbour secures $20M borrowing for Miami-Opa Locka airport project
• Rivian offers Q2 2026 revenue outlook, cash position grows